Dextromethorphan to Treat Patients With Voice Spasms
Condition: Voice Disorders
MeSH terms: Voice Disorders
Study type: Interventional
Phase: Phase 1

Summary: 
      This study will examine how dextromethorphan, a drug that alters reflexes of the larynx
      (voice box), might change voice symptoms in people with voice disorders due to uncontrolled
      laryngeal muscle spasms. These include abductor spasmodic dysphonia (breathy voice breaks),
      adductor spasmodic dysphonia (vowel breaks), muscular tension dysphonia (tight strained
      voice), and vocal tremor (tremulous voice). Dextromethorphan-one of a group of drugs called
      NMDA antagonists-has been used for years in over-the-counter cough suppressant medicines. In
      animal studies, the drug has blocked one of the reflexes in the larynx that may be associated
      with spasms in the laryngeal muscles. This study will compare the effects of
      dextromethorphan, lorazepam (a valium-type drug), and a placebo (inactive substance) in
      patients with the four types of voice disorders described above.

      Patients with spasmodic dysphonia, muscular tension dysphonia and vocal tremor may be
      eligible for this study. Individuals who smoke or use tobacco, who have vocal nodules or
      polyps, or who have a history of airway obstruction may not participate. Candidates will be
      screened with a medical history and physical examination, a questionnaire, voice recording
      (repeating sentences into a microphone), and nasolaryngoscopy (examination of the larynx with
      a tube advanced through the nose). For the nasolaryngoscopy, the inside of the nose is
      sprayed with a decongestant (to open the nasal passages) and possibly a local anesthetic. A
      small, flexible tube called a nasolaryngoscope is passed through the nose to look at the
      larynx during speech and other tasks, such as singing, whistling and prolonged vowels.

      Participants will be admitted to the NIH Clinical Center for each of three visits, which will
      last from the afternoon of one day to late afternoon of the following day. At each visit,
      patients will complete a questionnaire, baseline speech recording, and a test for sedation
      level. They will take three pills-either dextromethorphan, lorazepam, or placebo-one every 6
      hours. Vital signs will be checked every 6 hours and the level of sedation during waking
      hours will be monitored. One to three hours after taking the third pill, speech recording,
      questionnaire and test of sedation will be repeated to check for possible voice changes.
      Patients will be given a different pill at each visit.

      ...
    

Detailed description: 
      Studies of spasmodic dysphonia (SD) have increasingly pointed to the possibility of a central
      sensori-motor control disorder. Sensori-motor processing has been found abnormal in both
      adductor and abductor spasmodic dysphonia based on reflex conditioning studies. These studies
      demonstrated an increased frequency of R2 muscle responses during rapid paired presentation
      of electrical stimuli to the superior laryngeal nerve in spasmodic dysphonia. Thus,
      uncontrolled R2 responses were hypothesized to be the basis for the uncontrolled muscle
      bursts in these patients. Selective suppression of late R2 laryngeal adductor responses by
      N-methyl-D-Aspartate (NMDA) blockade in cats was demonstrated by Ambalavanar et.al. In
      particular, dextromethorphan reduced the frequency of R2 responses from 95% to 25% (P =
      0.015). Dextromethorphan is a widely used antitussive agent that has been in use for over 30
      years. In a double-blind randomized crossover design, 3 groups of patients will receive be
      randomly assigned to one of 6 order cohorts. They will then receive either dextromethorphan
      at a 8 mg/kg/d dose divided in a Q6 hour dosing schedule with only 3 doses administered PO
      every 6 hours for 3 dosages, 04 mg/kg/d of lorazepam PO every 6 hours for 3 dosages or a
      placebo administrated in the same way during Phase A. After a minimum of a 1-week washout
      interval, the patients will be given either the other medication or placebo during Phase B
      and then the remaining medication or placebo during Phase C.

      Our hypothesis is that dextromethorphan, an NMDA receptor blocker, will reduce voice breaks
      in spasmodic dysphonia to a greater degree than lorazepam, which has similar sedating side
      effects, but does not affect NMDA receptors with a different mechanism. On the other hand,
      patients with other idiopathic voice disorders, muscular tension dysphonia and vocal tremor,
      are hypothesized not to have a similar benefit from dextromethorphan. During the double-blind
      randomized cross-over study, three groups will be included, 10 patients with adductor or
      abductor spasmodic dysphonia, 10 with muscular tension dysphonia and 10 with vocal tremor.
      The results will determine if dextromethorphan has potential as a treatment option for
      patients with adductor or abductor SD.
    

Intervention name(s): Dextromethorphan; Lorazepam
Intervention type(s): Drug; Drug
Intervention MeSH terms: Lorazepam; Dextromethorphan
Primary purpose: Treatment
Keywords: Dextromethorphan; Sensorimotor Modulation; Spasmodic Dysphonia; Muscular Tension Dysphonia; Voice Tremor; Lorazepam; Dysphonia; Macular Tension Dysphonia